Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;56(3):342-350.
doi: 10.1007/s00120-016-0277-0.

[Second neoplasms after percutaneous radiotherapy]

[Article in German]
Affiliations
Review

[Second neoplasms after percutaneous radiotherapy]

[Article in German]
F Haidl et al. Urologe A. 2017 Mar.

Abstract

Radiation therapy represents an alternative treatment to radical prostatectomy in the management of clinically localized prostate cancer. Radiation-induced second neoplasms are defined by a latency period of at least 5 years, location within the field of radiation therapy, and a histology which differs from the primary tumor. Based on the data in the literature, there is a consistently increased risk of bladder cancer (HR: 1.67, 95% CI 1.55-1.80), rectal cancer (HR: 1.79, 95% CI 1.34-2.38), and colorectal cancer (HR: 1.79, 95% CI 1.34-23.8) following percutaneous radiation therapy. Following brachytherapy only an increased for the development of bladder cancer (HR: 2.14, 95% CI 1.03-3.94) has been observed. The incidence of second neoplasms increases significantly and continuously with the posttreatment time interval. Although bladder cancers following RT of the prostate are usually more locally advanced and of high grade, no negative impact in terms of overall survival and cancer-specific survival has been observed. Symptoms or findings of microhematuria need to be examined thoroughly after radiation therapy to identify bladder cancer quite early.

Keywords: Bladder cancer; Prostate cancer; Prostatectomy, radical; Radiotherapy; Rectal cancer.

PubMed Disclaimer

References

    1. J Urol. 2010 May;183(5):1751-6 - PubMed
    1. J Urol. 2015 Nov;194(5):1220-5 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):934-41 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):669-73 - PubMed
    1. Br J Cancer. 2015 Mar 17;112(6):977-82 - PubMed

MeSH terms

LinkOut - more resources